

September 9, 2025

TO: Pharmacies

FROM: Washington Apple Health

SUBJECT: Termination of federal rebate agreement - Xifaxan

Washington Apple Health (Medicaid) is alerting providers to the termination of federal rebate agreement for Xifaxan (rifaximin).

Effective October 1, 2025, claims for Xifaxan (rifaximin) may reject. There are no other rifaximin products with a federal rebate. If clients meet criteria for Early and Periodic Screening, Diagnostic, and Treatment services (EPSDT), providers should request prior authorization (PA) via EPSDT. Clients may also be eligible for the manufacturer patient assistance program.

Resources for patient assistance program:

- General Information: <https://www.bauschhealthpap.com/>
- Application: <https://www.bauschhealthpap.com/siteassets/pdf/docs/bh-pap-application-pap-medicaid.pdf>

For questions contact us at: [applehealthpharmacypolicy@hca.wa.gov](mailto:applehealthpharmacypolicy@hca.wa.gov)